Table 2.

Baseline and Post-Treatment Parameters of 20 Patients With Myelofibrosis Who Responded to Treatment With Pomalidomide and/or Prednisone

Patient No.	Patient Age/Sex	MF Subtype	Lille Score	JAK2 Status	Karyotype	Treatment Arm*	Hemoglobin Level (g/dL)		Response Duration (months)
							Pretreatment	Post-Treatment†
1	75/M	Primary	High	Neg	der(6)t(1q;6p)	POM	Tx dependent	9	3.2 (relapsed)
2	50/M	Primary	High	Neg	NA	POM	Tx dependent	13.3	9.2+
3	69/M	Primary	High	Neg	Normal	POM	8.1	10.9	6.4+
4	54/M	Primary	Int	Pos	+9	POM	Tx dependent	12.7	8.3+
5	79/M	Primary	Int	Pos	20q-	POM	Tx dependent	12.1	9.2+
6	63/F	Primary	Int	Pos	−7 and r(7)	POM/pred	9.9	16.0	14 (off-study)‡
7	68/M	Post-ET	High	Pos	Normal	POM/pred	Tx dependent	10.6	15.3+
8	65/F	Primary	Int	Pos	−7	POM/pred	Tx dependent	11	6.4+
9	72/M	Primary	Int	Pos	13q-	pom/pred	Tx dependent	10.8	4.1+
10	70/M	Post-ET	Int	Pos	NA	pom/pred	Tx dependent	10	6.5+
11	66/F	Primary	Int	Pos	NA	pom/pred	9.7	15.2	4.6+
12	60/M	Post-PV	High	Pos	Normal	pom/pred	Tx dependent	12.2	16.9+
13	43/M	Primary	Int	Neg	NA	pom/pred	Tx dependent	11.7	9.7+
14	59/F	Post-ET	Int	Neg	NA	pom/pred	Tx dependent	9.9	6.1+
15	59/M	Primary	Int	Pos	NA	pom/pred	Tx dependent	9.3	8.3+
16	86/F	Post-ET	Int	Pos	Normal	pom/pred	Tx dependent	11.6	14+
17	61/F	Primary	Int	Pos	Normal	Pred	Tx dependent	11.8	5.5 (relapsed)
18	58/F	Post-PV	Int	Pos	NA	Pred	8.3	12.4	2.8 (off-study)§
19	76/M	Primary	Int	Pos	NA	Pred	Tx dependent	9.4	2.3 (relapsed)
20	67/M	Primary	High	Neg	Normal	Pred	8.6	11.3	2.3+

NOTE. All responses signified improvement in anemia according to the International Working Group for Myelofibrosis Research and Treatment Criteria.¹⁷

Abbreviations: M, male; High, high risk; Neg, negative; POM, pomalidomide 2 mg/day; Tx, red blood cell transfusion; F, female; Pos, positive; pom, pomalidomide 0.5 mg/day; pred, prednisone; NA, not available; ET, essential thrombocythemia; PV, polycythemia vera; MF, myelofibrosis; Int, intermediate risk.

^*Please see text for treatment dose and schedule for both pomalidomide and prednisone.

^†Best hemoglobin response.

^‡Patient developed grade 3 pleural effusion attributed to drug.

^§Patient experienced progressive splenomegaly.